Global RNAi Technologies Report 2015 - Profiles of 161 Companies are Presented Along with 233 Collaborations

Nov 02, 2015, 12:10 ET from Research and Markets

DUBLIN, Nov. 2, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/md8zjk/rnai) has announced the addition of Jain PharmaBiotech's new report "RNAi - Technologies, Markets and Companies" to their offering.

The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2014 to 2024. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.

Because of its ability to silence any gene once the sequence is known, RNAi has been adopted as the research tool to discriminate gene function. After the genome of an organism is sequenced, RNAi can be designed to target every gene in the genome and target for specific phenotypes. Several methods of gene expression analysis are available and there is still need for sensitive methods of detection of gene expression as a baseline and measurement after gene silencing. RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes. RNAi is an important method for analyzing gene function and identifying new drug targets that uses double-stranded RNA to knock down or silence specific genes. With the advent of vector-mediated siRNA delivery methods it is now possible to make transgenic animals that can silence gene expression stably. These technologies point to the usefulness of RNAi for drug discovery.

Profiles of 161 companies involved in developing RNAi technologies are presented along with 233 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 35 are involved in microRNAs. The bibliography contains selected 640 publications that are cited in the report. The text is supplemented with 38 tables and 13 figures.

Key Topics Covered:

Executive Summary

1. Technologies for suppressing gene function 

2. RNAi Technologies

3. MicroRNA

4. Methods of delivery in RNAi

5. RNAi in Research

6. RNAi in drug discovery

7. Therapeutic applications of RNAi

8. Safety, regulatory and patent issues

9. Markets for RNAi Technologies

10. Companies involved in RNAi Technologies

11. References

For more information visit http://www.researchandmarkets.com/research/md8zjk/rnai

Source: Jain PharmaBiotech

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com